Evidence-driven manufacturing to expand pediatric cell therapy access in rare diseases
Active Other Transaction Agreement Awarded Last action
- Contract number
- 140D042690013
- Awardee
-
University Of Southern California UEI G88KLJR3KYT5
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $6,842,620
Award facts
- Contract value 100% obligated
- $6,842,620.00 Current and potential, with all options
- Completion date 31% complete
- Current and potential, with all options
- Funding agency
- National Institutes of Health Department of Health and Human Services
- NAICS code
- Not on record
- Competition
- Program Solicitation
- Pricing
- Other
- Place of performance
- Los Angeles, CA 90033, USA
Award details come from SAM.gov/FPDS.
About this award
The National Institutes of Health (NIH) awarded the University of Southern California an Other Transaction Agreement valued at $6.84M on February 27, 2026, for "Evidence-Driven Manufacturing to Expand Pediatric Cell Therapy Access in Rare Diseases," with completion targeted for March 31, 2028. This civilian research contract will be performed in Los Angeles, California, and represents NIH's investment in expanding access to advanced cell therapy treatments for pediatric patients with rare diseases through evidence-based manufacturing approaches. USC, a leading private research institution with extensive experience managing federal contracts and grants across healthcare, scientific research, and defense domains, will serve as the prime contractor with no designated set-asides, allowing open competition for subcontracting opportunities.
This award leverages USC's substantial capabilities in biomedical research and development, particularly its experience with cell engineering and therapeutic innovation as demonstrated through its current federal grant portfolio, which includes $1.99M in NIH funding for in vivo cell engineering approaches to HIV cure development. The Other Transaction Agreement structure provides flexibility in execution and allows USC to apply specialized expertise in pediatric cell therapy manufacturing while generating evidence to support broader clinical implementation and regulatory pathways. The contract reflects NIH's commitment to advancing pediatric rare disease treatments through rigorous, data-driven manufacturing methodologies that could improve patient access and outcomes in this underserved patient population.
Quick answers
Who was awarded contract 140D042690013?
140D042690013 was awarded to University Of Southern California by Interior Business Center (Office of Policy Management and Budget) on February 27, 2026.
How much is contract 140D042690013 worth?
The government has obligated $6,842,620 on 140D042690013.
Which agency awarded contract 140D042690013?
Interior Business Center (Office of Policy Management and Budget) awarded 140D042690013, with funding from National Institutes of Health (Department of Health and Human Services).
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award